| Online-Ressource |
Verfasst von: | Giesel, Frederik L. [VerfasserIn]  |
| Will, Leon [VerfasserIn]  |
| Kratochwil, Clemens [VerfasserIn]  |
| Haberkorn, Uwe [VerfasserIn]  |
Titel: | Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma |
Titelzusatz: | a pilot study |
Verf.angabe: | Frederik Giesel, Leon Will, Ismaheel Lawal, Thabo Lengana, Clemens Kratochwil, Mariza Vorster, Oliver Neels, Florette Reyneke, Uwe Haberkon, Klaus Kopka, and Mike Sathekge |
Jahr: | 2018 |
Umfang: | 5 S. |
Fussnoten: | Published online: December 21, 2017 ; Im Titel falsche Schreibweise von Uwe Haberkorn ; Im Titel ist "18" hochgestellt ; Gesehen am 21.06.2018 |
Titel Quelle: | Enthalten in: Journal of nuclear medicine technology |
Ort Quelle: | New York, NY : Soc., 1973 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 59(2018), 7, Seite 1076-1080 |
ISSN Quelle: | 1535-5675 |
Abstract: | Introduction: The introduction of 18F-labelled prostate-specific membrane antigen (PSMA) targeted positron emission tomography/computed-tomography (PET/CT) tracers, firstly 18F-DCFPyL and more recently 18F-PSMA-1007, have demonstrated promising results for the diagnostic workup of prostate cancer (PCa). This clinical study presents an intra-individual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL versus 18F-PSMA-1007. Methods: Twelve prostate cancer patients, drug naive or prior to surgery, received similar activities of about 250 MBq 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h p.i. in the same PET/CT-scanner using the same reconstruction-algorithm. Normal organ biodistribution and tumor uptakes were quantified using SUVmax. Results: PSMA-positive lesions were detected in twelve out of twelve PCa patients. Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the identical lesions. No statistical significance could be observed when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases and bone metastases. With regard to normal organs, 18F-DCFPyL presented statistically significant higher uptake in kidneys, urinary bladder and lacrimal gland. Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007 resulting in identical clinical findings for the evaluated routine situations. Non-urinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph-node metastasis in selective patients; the lower hepatic background might favor 18F-DCFPyL in very late stages when rare cases of liver metastases can occur. |
DOI: | doi:10.2967/jnumed.117.204669 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.2967/jnumed.117.204669 |
| Volltext: http://jnm.snmjournals.org/content/early/2017/12/20/jnumed.117.204669 |
| DOI: https://doi.org/10.2967/jnumed.117.204669 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | 18F-DCFPyL |
| 18F-PSMA-1007 |
| Molecular Imaging |
| Oncology: GU |
| PET/CT |
| Prostate carcinoma |
| PSMA |
K10plus-PPN: | 157644404X |
Verknüpfungen: | → Zeitschrift |
Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma / Giesel, Frederik L. [VerfasserIn]; 2018 (Online-Ressource)